Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
DOI: 10.1016/S2468-1253(25)00267-5
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2468125325002675
其他信息:
出版社: Elsevier BV
作者: Jian Li; Zhenghang Wang; Jing Huang; Yi Ba; Baoshan Cao; Suxia Luo; Wenhua Li; Chunmei Bai; Zhengbo Song; Jianping Xiong; Liangjun Zhu; Guangyu An; Yanqiao Zhang; Zhihua Li; Yongsheng Li; Yanhong Gu; Changlu Hu; Xingya Li; Chenghui Huang; Qihan Fu; Xianli Yin; Xinjun Liang; Diansheng Zhong; Huaqiu Shi; Xiaoyan Li; Zhen Li; Lian Liu; Feng Wang; Rong Liang; Guohao Xia; Zhen Wang; Andrea Wang-Gillam; Yuli Ding; Zhiyue Rao; Wenhui Pan; Shuang Lu; Xin Sun; Lin Shen

